Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Nasopharyngeal Neoplasms

imatinib mesylate has been researched along with Nasopharyngeal Neoplasms in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kapoor, S1
Hong, MH; Huang, PY; Luo, DH; Mai, HQ; Zhang, L; Zhang, X1
Brown, MC; Casasola, RJ1
Chen, A; Chen, YF; Kao, WY; Lee, WC; Sheu, LF; Young, ZH1

Other Studies

4 other study(ies) available for imatinib mesylate and Nasopharyngeal Neoplasms

ArticleYear
The therapeutic benefits of heme oxygenase (HO-1) inhibition in the management of systemic malignancies besides hepatocellular carcinomas.
    International journal of cancer, 2009, Aug-01, Volume: 125, Issue:3

    Topics: Antineoplastic Agents; Benzamides; Carcinoma, Hepatocellular; Enzyme Inhibitors; Heme Oxygenase-1; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Neoplasms; Nasopharyngeal Neoplasms; Neoplasms; Piperazines; Protoporphyrins; Pyrimidines; Sarcoma, Kaposi

2009
C-KIT overexpression and mutation in nasopharyngeal carcinoma cell lines and reactivity of Imatinib on these cell lines.
    Chinese journal of cancer, 2010, Volume: 29, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Epithelial Cells; Herpesvirus 4, Human; Heterozygote; Homozygote; Humans; Imatinib Mesylate; Introns; Mutation; Nasopharyngeal Neoplasms; Nasopharynx; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines

2010
Complete response in a melanoma patient treated with imatinib.
    The Journal of laryngology and otology, 2012, Volume: 126, Issue:6

    Topics: Antineoplastic Agents; Benzamides; Exons; Gene Expression; Humans; Imatinib Mesylate; Male; Melanoma; Middle Aged; Mutation; Nasopharyngeal Neoplasms; Neoplasm Staging; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Treatment Outcome

2012
STI571 sensitizes nasopharyngeal carcinoma cells to cisplatin: sustained activation of ERK with improved growth inhibition.
    International journal of oncology, 2007, Volume: 30, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Carcinoma; Cell Death; Cell Proliferation; Cisplatin; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Male; Mice; Nasopharyngeal Neoplasms; Neoplasm Transplantation; Phosphorylation; Piperazines; Pyrimidines

2007